What are the expectations for the upcoming FY 2025/26 guidance, especially regarding the product pipeline and upcoming product launches? | COLO (Aug 08, 2025) | Candlesense
COLO

What are the expectations for the upcoming FY 2025/26 guidance, especially regarding the product pipeline and upcoming product launches?

The notice you provided relates only to the 19 August 2025 conference call where Coloplast will present its 9‑month 2024/25 interim results. It does not contain any details about the FY 2025/26 guidance, the product pipeline, or planned product launches.

To obtain the information you’re looking for, you’ll need to refer to the materials that will be released in conjunction with the conference call—specifically:

  1. The interim earnings release (expected around 07:30 CEST on 19 August 2025).
  2. The accompanying presentation (available roughly an hour before the call).
  3. The transcript or webcast recording of the conference call itself.

These documents are where Coloplast typically outlines its outlook for the next fiscal year, including any updates on new products in development and upcoming launches.

If you have access to those materials after the call, you should find the FY 2025/26 guidance and pipeline details there. Otherwise, you may want to monitor Coloplast’s investor‑relations website or future press releases for the official guidance.

Other Questions About This News

What is the current free cash flow generation and its impact on planned share buy‑backs or capital allocation? Are there any upcoming catalysts or events (e.g., regulatory approvals, M&A activity, conferences) that could influence the stock price in the near term? How did the 9M 2024/25 earnings compare to analyst expectations and consensus forecasts? Are there any changes to the dividend policy or payout ratio following the interim results? Did management comment on any macro‑economic or regulatory risks that could affect future performance? Which Business Units (e.g., Colostomy, Urology, Wound Care) drove the performance, and were there any notable segment trends? What is the outlook for full‑year 2024/25 earnings and guidance – any revisions to revenue, EBITDA, or EPS forecasts? How does the current valuation (P/E, EV/EBITDA) compare to key competitors in the medical device sector after this release? How did currency fluctuations (euro, US $) affect the reported results, and what hedging strategies are in place? What is the expected impact of the 9M results on the stock’s technical indicators (e.g., support/resistance levels) in the short‑term? What were the revenue growth rates and margins for the 9 months, and how do they compare year‑over‑year and to the prior quarter?